Latest Rare Disease Therapeutics Inc. Stories
PURIXAN(TM) (mercaptopurine) Oral Suspension Finally Makes Accurate Dosing Simple for Healthcare Professionals to Achieve--Especially with Children FRANKLIN, Tenn., April 30, 2014 /PRNewswire/ -- Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN(TM) (mercaptopurine) 20 mg/mL oral suspension---a new, easier-to-dose, liquid form of an established treatment for...
- A spider.
- Figuratively, a peevish, testy, ill-natured person.